157 related articles for article (PubMed ID: 38429536)
1. Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature.
Mercadal S; Mussetti A; Lee CJ; Arevalo C; Odstrcil SM; Peña E; Sureda A; Couriel DR
Ann Hematol; 2024 May; 103(5):1717-1727. PubMed ID: 38429536
[TBL] [Abstract][Full Text] [Related]
2. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
3. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
[TBL] [Abstract][Full Text] [Related]
4. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study.
Le Calvez B; Tessoullin B; Renaud L; Botella-Garcia C; Srour M; Le Gouill S; Guillerm G; Gressin R; Nguyen Quoc S; Furst S; Chauchet A; Sibon D; Lewalle P; Poiré X; Maillard N; Villate A; Loschi M; Paillassa J; Beguin Y; Dulery R; Tudesq JJ; Fayard A; Béné MC; Camus V; Chevallier P; Le Bourgeois A
Acta Oncol; 2022 Nov; 61(11):1332-1338. PubMed ID: 36214787
[No Abstract] [Full Text] [Related]
6. The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma.
Min GJ; Jeon YW; Kim TY; Kwag D; Kim BS; Lee J; Lee JH; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Cho SG
Sci Rep; 2023 Oct; 13(1):17496. PubMed ID: 37840059
[TBL] [Abstract][Full Text] [Related]
7. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas.
Massoud R; Naim H; Klyuchnikov E; Janson D; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2024 Feb; 112(2):276-285. PubMed ID: 37845834
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
10. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
[TBL] [Abstract][Full Text] [Related]
11. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem cell transplantation for B-cell lymphoma in Taiwan.
Lee CH; Lin TC; Yao M; Hsiao LT; Ko BS; Liu CJ; Chen TY
Cancer Med; 2023 Dec; 12(24):21761-21769. PubMed ID: 38018321
[TBL] [Abstract][Full Text] [Related]
14. A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China.
Gu ZY; Dong YJ; Fu XR; Li NN; Liu Y; Wu XX; Wang YN; Li YH; Ren HY; Zhang MZ; Li XF; Wang MH; Wu YM; Liu DH; Wang Z; Hu LD; Huang WR
Chin Med J (Engl); 2021 Jun; 134(13):1584-1592. PubMed ID: 34133361
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma.
Fried S; Shouval R; Walji M; Flynn JR; Yerushalmi R; Shem-Tov N; Danylesko I; Tomas AA; Fein JA; Devlin SM; Sauter CS; Shah GL; Kedmi M; Jacoby E; Shargian L; Raanani P; Yeshurun M; Perales MA; Nagler A; Avigdor A; Shimoni A
Transplant Cell Ther; 2023 Feb; 29(2):99-107. PubMed ID: 36343892
[TBL] [Abstract][Full Text] [Related]
16. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
17. [CAR T-cell bridging to allo-HSCT for relapsed/refractory B-cell acute lymphoblastic leukemia: the follow-up outcomes].
Yan M; Wu YJ; Chen F; Tang XW; Han Y; Qiu HY; Sun AN; Xue SL; Jin ZM; Wang Y; Miao M; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):710-715. PubMed ID: 33113601
[No Abstract] [Full Text] [Related]
18. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
19. [Therapeutic effect of CY-fTBI and BMM conditioning regimen in the process of allo-HSCT treating Ⅲ,Ⅳ non-Hodgkin lymphoma: 15 years analysis of single-center].
Sun T; Hu L; Jiang M; Ning H; Zhang B; Ren J; Li Y; Li B; Chen J; Yang F; Xu C; Wang J; Lou X; Hu J; Chen H
Zhonghua Xue Ye Xue Za Zhi; 2015 Oct; 36(10):830-4. PubMed ID: 26477760
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
